Multidisciplinary Management of Hepatocellular Carcinoma

  • Ahmed O. Kaseb
  • Yasmin M. Abaza
  • Robert E. Roses
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 190)


Treatment of HCC is complicated by its highly variable biologic behavior and the frequent coexistence of chronic liver disease and cirrhosis in affected patients. While surgery remains the most frequently employed treatment modality, curative resection is only possible for a minority of patients. More often, treatment goals are palliative and draw on the expertise of a range of medical specialists. This chapter aims to place current treatment strategies within the framework of a multidisciplinary approach with special emphasis on pretreatment evaluation, staging, and the selection of an appropriate treatment strategy.


Portal Vein Embolization Future Liver Remnant Barcelona Clinic Liver Cancer Milan Criterion Magnetic Resonance Elastography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRefGoogle Scholar
  2. 2.
    Vauthey JN, Lauwers GY, Esnaola NF et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536PubMedCrossRefGoogle Scholar
  3. 3.
    Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469PubMedCrossRefGoogle Scholar
  4. 4.
    Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38:1449–1457PubMedGoogle Scholar
  5. 5.
    Ishizawa T, Hasegawa K, Aoki T et al (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–1916PubMedCrossRefGoogle Scholar
  6. 6.
    Teh SH, Christein J, Donohue J et al (2005) Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9:1207–1215PubMedCrossRefGoogle Scholar
  7. 7.
    Cucchetti A, Ercolani G, Vivarelli M et al (2006) Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 12:966–971PubMedCrossRefGoogle Scholar
  8. 8.
    Capussotti L, Ferrero A, Vigano L et al (2006) Portal hypertension: contraindication to liver surgery? World J Surg 30:992–999PubMedCrossRefGoogle Scholar
  9. 9.
    Iannaccone R, Laghi A, Catalano C et al (2005) Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 234:460–467PubMedCrossRefGoogle Scholar
  10. 10.
    Laghi A, Iannaccone R, Rossi P et al (2003) Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 226:543–549PubMedCrossRefGoogle Scholar
  11. 11.
    Rode A, Bancel B, Douek P et al (2001) Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 25:327–336PubMedCrossRefGoogle Scholar
  12. 12.
    Burrel M, Llovet JM, Ayuso C et al (2003) MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38:1034–1042PubMedGoogle Scholar
  13. 13.
    Kim HJ, Kim KW, Byun JH et al (2006) Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. AJR Am J Roentgenol 186:1059–1066PubMedCrossRefGoogle Scholar
  14. 14.
    Frericks BB, Loddenkemper C, Huppertz A et al (2009) Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 193:1053–1060PubMedCrossRefGoogle Scholar
  15. 15.
    Hammerstingl R, Huppertz A, Breuer J et al (2008) Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18:457–467PubMedCrossRefGoogle Scholar
  16. 16.
    Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet, 362:1907–1917PubMedCrossRefGoogle Scholar
  17. 17.
    Jung G, Breuer J, Poll LW et al (2006) Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 47:15–23PubMedCrossRefGoogle Scholar
  18. 18.
    Bhartia B, Ward J, Guthrie JA et al (2003) Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am J Roentgenol 180:577–584PubMedGoogle Scholar
  19. 19.
    Lee VS, Hecht EM, Taouli B et al (2007) Body and cardiovascular MR imaging at 3.0 T. Radiology 244:692–705PubMedCrossRefGoogle Scholar
  20. 20.
    Mannelli L, Kim S, Hajdu CH et al (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193:1044–1052PubMedCrossRefGoogle Scholar
  21. 21.
    Huwart L, Sempoux C, Vicaut E et al (2008) Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135:32–40PubMedCrossRefGoogle Scholar
  22. 22.
    Hagiwara M, Rusinek H, Lee VS et al (2008) Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging—initial experience. Radiology 246:926–934PubMedCrossRefGoogle Scholar
  23. 23.
    Forner A, Vilana R, Ayuso C et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104PubMedCrossRefGoogle Scholar
  24. 24.
    DuBay D, Sandroussi C, Sandhu L et al (2011) Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 253:166–172PubMedCrossRefGoogle Scholar
  25. 25.
    Vauthey JN, Dixon E, Abdalla EK et al (2010) Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 12:289–299Google Scholar
  26. 26.
    Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRefGoogle Scholar
  27. 27.
    Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338PubMedCrossRefGoogle Scholar
  28. 28.
    Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRefGoogle Scholar
  29. 29.
    Cillo U, Bassanello M, Vitale A et al (2004) The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 40:124–131PubMedCrossRefGoogle Scholar
  30. 30.
    Cillo U, Vitale A, Grigoletto F et al (2006) Prospective validation of the Barcelona clinic liver cancer staging system. J Hepatol 44:723–731PubMedCrossRefGoogle Scholar
  31. 31.
    Jonas S, Al-Abadi H, Benckert C et al (2009) Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 250:1008–1013PubMedCrossRefGoogle Scholar
  32. 32.
    Poon RT, Lau C, Pang R et al (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835–1845PubMedCrossRefGoogle Scholar
  33. 33.
    Kaseb AO, Abbruzzese JL, Vauthey JN et al (2011) I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 80:373–381PubMedCrossRefGoogle Scholar
  34. 34.
    Prasad KR, Young RS, Burra P et al (2011) Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 17(Suppl 2):S81–89PubMedCrossRefGoogle Scholar
  35. 35.
    Belghiti J (2009) Resection and liver transplantation for HCC. J Gastroenterol 44(Suppl 19):132–135PubMedCrossRefGoogle Scholar
  36. 36.
    Cherqui D, Laurent A, Mocellin N et al (2009) Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 250:738–746PubMedCrossRefGoogle Scholar
  37. 37.
    Otsuka Y, Duffy JP, Saab S et al (2007) Postresection hepatic failure: successful treatment with liver transplantation. Liver Transpl 13:672–679PubMedCrossRefGoogle Scholar
  38. 38.
    Scatton O, Zalinski S, Terris B et al (2008) Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl 14:779–788PubMedCrossRefGoogle Scholar
  39. 39.
    Kulik LM, Atassi B, van Holsbeeck L et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586PubMedCrossRefGoogle Scholar
  40. 40.
    Lewandowski RJ, Kulik LM, Riaz A et al (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9:1920–1928PubMedCrossRefGoogle Scholar
  41. 41.
    Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739PubMedCrossRefGoogle Scholar
  42. 42.
    A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med (1995) 332:1256–1261Google Scholar
  43. 43.
    Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedCrossRefGoogle Scholar
  44. 44.
    Schwarz RE, Abou-Alfa GK, Geschwind JF et al (2010) Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 12:313–320Google Scholar
  45. 45.
    Krishnan S, Dawson LA, Seong J et al (2008) Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 15:1015–1024PubMedCrossRefGoogle Scholar
  46. 46.
    Hawkins MA, Dawson LA (2006) Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106:1653–1663PubMedCrossRefGoogle Scholar
  47. 47.
    Chiba T, Tokuuye K, Matsuzaki Y et al (2005) Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 11:3799–3805PubMedCrossRefGoogle Scholar
  48. 48.
    Kawashima M, Furuse J, Nishio T et al (2005) Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23:1839–1846PubMedCrossRefGoogle Scholar
  49. 49.
    Yasuda S, Ito H, Yoshikawa M et al (1999) Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol 15:467–473PubMedGoogle Scholar
  50. 50.
    Seong J, Keum KC, Han KH et al (1999) Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 43:393–397PubMedCrossRefGoogle Scholar
  51. 51.
    Guo WJ, Yu EX (2000) Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 73:1091–1097PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Ahmed O. Kaseb
    • 1
  • Yasmin M. Abaza
    • 1
  • Robert E. Roses
    • 1
  1. 1.Department of Gastrointestinal Medical Oncology, Department of Surgical OncologyThe University of TexasHoustonUSA

Personalised recommendations